Logo Image

Videos

H3B-6527 Demonstrates Tolerability in Phase I Trial for Patients With Advanced HCC

ByMartin E. Gutierrez, MD

Martin E. Gutierrez, MD, director, Drug Discovery/Phase I Unit, and co-chief and medical oncologist, Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses the early findings for H3B-6527, an FGFR4 inhibitor, as a treatment of patients with hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma

Delivering Precise Immunotherapy With NGS in NSCLC

ByCharu Aggarwal, MD, MPH

Charu Aggarwal, MD, MPH, the Leslye M. Heisler Assistant Professor for Lung Cancer Excellence at Perelman School of Medicine, University of Pennsylvania, and other researchers conducted a prospective study using next-generation sequencing as a biomarker to predict response and progression-free survival rates in patients with non–small cell lung cancer  receiving pembrolizumab monotherapy. The data were presented during the 2019 ASCO Annual Meeting.

The Rationale for Dostarlimab Monotherapy In MSI-H and MSS Endometrial Cancer

ByAna Oaknin, MD

Ana Oaknin, MD, head of the Gynecologic Tumors Unit, Vall d’Hebron University Hospital, and principal investigator, Gynecological Malignancies Group, explains the rationale for analyzing anti–PD-1 monotherapy with dostarlimab in patients with microsatellite instability–high and microsatellite stable endometrial cancer. 

Achieving MFS and Improved Quality of Life in nmCRPC With Darolutamide

ByKarim Fizazi, MD, PhD

Karim Fizazi, MD, PhD,head of the Department of Cancer Medicine,&nbsp;Institut Gustave Roussy, University of Paris-Sud, gives highlights on the updated findings from the phase III ARAMIS trial using darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer, recently presented during the 2019 ASCO Annual Meeting.&nbsp;<br /> &nbsp;